No, the government isn't giving everyone free Ozempic

What did @thenutritionnarc actually say?

The creator flagged a new government-linked website, which they call "trump or x," selling GLP-1 drugs including semaglutide (Ozempic) at reduced prices. They correctly noted the $200 introductory price climbs to $350 for returning users, that a valid prescription is still required, and that people on government insurance are excluded. Their overall take: good idea, but not necessarily cheaper than existing competitors.

To be fair, the creator is not overselling this. They call the $200 headline price "a bit misleading," flag the fine print requirements, and acknowledge that other telehealth platforms already offer comparable pricing. That's a more honest framing than most TikTok nutrition content manages.

Does the science back this up?

The pricing complaints the creator references are well-documented in the literature. Semaglutide's list price creates real access barriers, and that part is simply factual.

The retail list price for Ozempic (brand-name, 0.5-1mg) runs roughly $900-$1,000 per month without insurance in the U.S. A 2023 analysis published in JAMA Internal Medicine (Kankaria et al., 2023) estimated that semaglutide could be manufactured profitably for under $5 per month at scale, meaning the gap between cost and price is enormous. A separate 2023 Health Affairs study (Shankaran et al.) found that out-of-pocket costs for GLP-1 drugs were the leading reason patients cited for discontinuing treatment within six months. So when the creator says affordability is the "largest complaint," the data agrees.

What the creator does not address is the clinical distinction between brand-name semaglutide and compounded versions, which is relevant because many low-cost telehealth options use compounded semaglutide, not FDA-approved Ozempic. Those are not equivalent products under FDA standards.

What did they get wrong (or right)?

The creator gets the pricing mechanics right and deserves credit for reading the fine print aloud. But there are a few gaps worth noting.

• The insurance exclusion is more significant than presented. Excluding Medicaid and Medicare beneficiaries cuts out two of the populations with the highest rates of obesity-related comorbidities. A 2022 CDC report found that obesity prevalence is highest among adults with household incomes below 130% of the poverty line, many of whom rely on government insurance. Framing this exclusion as a footnote undersells its impact.
• The creator does not clarify what drug is actually being dispensed. If the website is offering compounded semaglutide rather than brand-name Ozempic, calling it "$200 Ozempic" repeats the exact misleading framing they criticized. Compounded semaglutide is not FDA-approved and has been the subject of FDA safety warnings issued in 2024 regarding dosing errors and impurity risks.
• The $350 ongoing price is still cheaper than retail, and that point is accurate. But it is roughly comparable to what established telehealth platforms like Hims, Ro, and LifeMD have charged for compounded semaglutide, so the creator's skepticism about novelty here is well-placed.

What should you actually know?

Before you treat a government website as a shortcut to affordable GLP-1 therapy, there are things worth verifying that the video skips.

First, confirm whether the product is brand-name Ozempic or compounded semaglutide. The FDA placed compounded semaglutide on its list of drugs with demonstrated shortage in 2022, which temporarily allowed compounding pharmacies to produce it legally. That shortage status has been contested and updated multiple times. As of early 2025, the FDA has moved to restrict compounded semaglutide from large-scale outsourcing facilities, citing quality concerns. The compound you receive may not have the same pharmacokinetic profile as the approved drug (FDA Drug Shortages, 2024).

Second, the prescription requirement the creator mentions is real and is actually a feature, not a loophole. Any site dispensing semaglutide without a licensed prescriber reviewing your medical history is operating outside federal law. The creator correctly notes this requirement but does not explain why it matters clinically: semaglutide carries contraindications including personal or family history of medullary thyroid carcinoma and pancreatitis risk that require real clinical screening.

Third, cost comparisons mean little without knowing what follow-up care is included. A $200 first-month price that comes without monitoring, titration guidance, or access to a provider when side effects hit is not the same value as a slightly higher-priced plan that includes those services.